Table 1.
Patient demographics and baseline characteristics
| Characteristic | N = 51 |
|---|---|
| Age, n (%) | |
| <65 years | 28 (54.9) |
| ≥65 years | 23 (45.1) |
| Median (range), years | 64.0 (31–84) |
| Sex, n (%) | |
| Male | 34 (66.7) |
| Female | 17 (33.3) |
| Race, n (%) | |
| White | 35 (68.6) |
| Asian | 2 (3.9) |
| American Indian or Alaskan | 1 (2.0) |
| Black or African American | 1 (2.0) |
| Other | 12 (23.5) |
| ECOG performance status, n (%) | |
| 0 | 25 (49.0) |
| 1 | 26 (51.0) |
| Site of primary tumor, n (%) | |
| Cutaneous | 28 (54.9) |
| Ocular | 16 (31.4) |
| Mucosal | 2 (3.9) |
| Othera | 5 (9.8) |
| Time from initial diagnosis to study entry, years | |
| Median | 4.3 |
| Range | 0.3–33.5 |
| Time since first metastatic disease, months | |
| Median | 14.8 |
| Range | 2.3–168.9 |
| PD-L1 expression (≥1% of tumor cells), n (%) | |
| Positive | 19 (37.3) |
| Negative | 20 (39.2) |
| Not evaluable | 12 (23.5) |
| Number of prior lines of therapy for metastatic or locally advanced disease, n (%) | |
| 0 | 1 (2.0) |
| 1 | 23 (45.1) |
| 2 | 17 (33.3) |
| ≥3 | 9 (18.0) |
| Missing | 1 (2.0) |
| Median (range) | 2 (0–4) |
| Prior anticancer therapy in >5% of patients, n (%) | |
| Ipilimumab | 26 (51.0) |
| Dacarbazine | 11 (21.6) |
| Cisplatin | 8 (15.7) |
| Interferon | 6 (11.8) |
| Fotemustine | 5 (9.8) |
| Gemcitabine | 5 (9.8) |
| Treosulfan | 5 (9.8) |
| Vemurafenib | 5 (9.8) |
| Investigational drug | 4 (7.8) |
| Paclitaxel | 3 (5.9) |
| Sorafenib | 3 (5.9) |
a Includes melanoma of the canthus (n = 1) and unknown primary (n = 4)